Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

About this update from Zymeworks Inc.

[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Mr3NL5l3JfRng99mnVVlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Investment industry veteran Mr. Brian Cherry appointed to Board of Directors","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating Officer","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"Five new Vice Presidents appointed, underscoring our commitment to leadership development","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":331,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company’s corporate strategy announced in November.","length":535,"tagName":"p"},{"type":"text","content":"“At Zymeworks, we recognize that our greatest asset is our people. Ensuring that we continue to have the right set of key skills and experience within our Board of Directors and leadership team is critical for successful execution of our current strategy and driving long-term shareholder value. Elevating talented individuals at Zymeworks recognizes their strong performance for the Company, our continued confidence in their abilities and the emphasis we place on cultivating leaders from within,” said Kenneth Galbraith, Chair, Chief Executive Officer, and Acting Chief Financial Officer of Zymeworks.","length":604,"tagName":"p"},{"type":"...

More updates from Zymeworks Inc.